Treatments and new perspectives of Antiphospholipid Syndrome in pregnancy

Abstract

Antiphospholipid syndrome (APS) is characterized by thrombosis and/or recurrent miscarriage and the presence of persistent antiphospholipid antibodies (aPL). APS during pregnanvy represents an increased risk of miscarriage and thrombotic events for the woman and fetus. The treatment of APS is based on lifetime anticoagulation therapy, using aspirin which may be combined with heparin. However, many reports show that women can be refractory to this treatment. In spite of attempts to develop new therapies, the treatment outcomes for APS in pregnancy remain poor. The development of new therapeutic modalities is needed to treat and/or prevent thrombosis in pregnant patients with APS and protect the fetus.